Effectiveness of Bortezomib in Cardiac AL Amyloidosis: A Report of Two Cases

Table 2

Followup of case report 2.

	January 2005; Basal	April 2005; after melp/pr 2 cycles	September 2006; after dex/thalidomide	January 2007; after 2 cycles of melp/dex (Figure 3)	July 2007; before bort/dex	June 2008; after bort/dexa 6 cycles (Figure 4)	October; 2008 (Figure 5)
Serum free 𝑘 light chains; mg/dL (n.v. < 19.4 )	92	63	174	134	331	149	189
𝑘/𝜆 ratio; (0.26–1.65)	6.13	2.92	2.95	4.4	7.4	4.53	5.57
BNP pg/mL; (n.v. < 50)		81	2976	2480	3138	484	1292
Troponin I ng/mL; (n.v. < 0.06)		0.05	0.04	0.02	0.04	0.04	0.07
IVS (mm)	9	11	13	17		12	14
LVPPW (mm)	9	10	13	15		12	13

mel: melphalan; pr: prednisone; dex: dexamethasone; bort: bortezomib.